When I was first interviewing oncologists to decide whom to put on my team to help me deal with my prostate cancer recurrence, I remember leaving the office of the doctor I eventually selected and saying to my wife, “I can’t use him.” She asked why and I replied, “He is not going to be [...]
Stories abound about men who undergo prostate cancer surgery only to have the surgery halted when their doctor sees that the cancer has left the gland. The stories go that the doctor stops the surgery leaving the gland and any other visible tumors in place just as they found them. Current statistics indicate that one [...]
A multi-center Phase III study discussed at the 2009 meeting of the American Urological Association,[1] has demonstrated that the risk for bone fractures in men on androgen deprivation therapy (ADT) can be reduced by using toremifene (Acapodene). Men, fighting advanced prostate cancer, often receive long-term ADT, which along with other side effects will increase their [...]
Confirming a belief of many of us, new research has found that hormone therapy (endocrine therapy or ADT) is associated with a very large increased risk of developing various major heart problems. This research also tells us that some therapy options have a higher risk profile than others. At Europe's biggest cancer congress, ECCO 15 [...]
Advanced prostate cancer poses a deadly paradox for younger men (aged 35 to 44 years). Younger men diagnosed with advanced prostate cancer will have a shorter remaining life span than older men who develop the disease, despite the fact that in general younger men have a much lower risk of dying from prostate cancer. Daniel [...]